Bristol-Myers Squibb Company
Pharmaceuticals and BiotechnologyFounded 1989- Updated June 2025
Reviewed by Swet Parvadiya
Last reviewed: June 2025
CorpDigest
Bristol-Myers Squibb Company
Company History
Founded 1989 in New York, New York
Last reviewed: 2025-06-08 · By Swet Parvadiya
Squibb was founded in 1858 by Edward Robinson Squibb, a Navy pharmacist who was so disturbed by the quality of medicines supplied to military hospitals that he started manufacturing his own.
Edward Robinson Squibb was born in 1819 in New York, and after a distinguished career as a naval physician, he became frustrated by the impure and inconsistent quality of medical supplies used during the Mexican-American War and the early days of the Civil War. His decision to found his own pharmaceutical manufacturing company in Brooklyn, New York, in 1858 was driven by the explicit goal of applying rigorous scientific standards to the production of chemicals and medicines, ensuring that every batch met the highest possible purity standards. This focus on quality was not merely a moral imperative; it was a revolutionary business strategy that allowed the company to build brand trust, scale production, and establish a distribution network that would eventually span the globe. Squibb's shrewd business acumen and his willingness to invest heavily in proprietary manufacturing processes allowed the young company to carve out a niche in the growing market for patented, branded medicinal products, despite intense competition from established chemical manufacturers. His leadership laid the groundwork for the company's subsequent pivot to the industrial production of antibiotics during World War II, a move that would transform the company into a global biopharmaceutical powerhouse and generate the massive cash flows that funded its entry into the oncology and cardiovascular markets. Squibb's legacy is defined by his understanding that the future of healthcare lay in bringing scientific rigor and industrial efficiency to the business of human health, a philosophy that remains the bedrock of the organization's operations today.
Clinton F. Bristol was born in 1853 in Massachusetts, and after a brief career in the patent medicine industry, he recognized a critical flaw in the consumer health market of the late 19th century: the efficacy of over-the-counter medicines was entirely dependent on the inconsistent quality of their ingredients, a problem that plagued consumers and limited the scalability of treatments. His decision to co-found the Clinton Pharmaceutical Company in 1887 was driven by the explicit goal of applying industrial manufacturing principles to the production of proprietary medicines, ensuring that every batch contained a precise, standardized dose of the active compound. This focus on standardization was not merely a quality control measure; it was a revolutionary business strategy that allowed the company to build brand trust, scale production, and establish a distribution network that would eventually span the globe. Bristol's shrewd business acumen and his willingness to invest heavily in proprietary manufacturing processes allowed the young company to carve out a niche in the growing market for patented, branded medicinal products, despite intense competition from established chemical manufacturers. His leadership laid the groundwork for the company's subsequent pivot to the industrial production of antibiotics and other complex biologics in the mid-20th century, a move that would transform the company into a global biopharmaceutical powerhouse and generate the massive cash flows that funded its entry into the oncology and cardiovascular markets. Bristol's legacy is defined by his understanding that the future of healthcare lay in bringing scientific rigor and industrial efficiency to the business of human health, a philosophy that remains the bedrock of the organization's operations today.
Edward Robinson Squibb founded the company in Brooklyn, New York, with the explicit vision of producing chemicals and medicines of the highest possible purity, establishing the foundational business model of rigorous scientific quality control and industrial-scale pharmaceutical manufacturing.
Clinton F. Bristol and John K. Bristol co-founded the Clinton Pharmaceutical Company in Clinton, Massachusetts, with the vision of producing standardized, high-quality proprietary medicines, establishing the foundational business model of scalable, reliable consumer health manufacturing.
Squibb achieved the commercial-scale production of penicillin, followed by the rapid commercialization of other antibiotics, transforming the company from a modest chemical manufacturer into a global biopharmaceutical powerhouse and capturing a dominant market share in the anti-infective market.
Bristol-Myers and Squibb completed a $12.0 billion merger, combining the deep scientific expertise and oncology franchise of Squibb with the massive commercial infrastructure and consumer health portfolio of Bristol-Myers, creating a global biopharmaceutical entity with the scale and resources to compete with the largest players in the industry.
The FDA approved Yervoy (ipilimumab), the first immune checkpoint inhibitor to demonstrate a survival benefit in advanced melanoma, establishing the organization's leadership in the immuno-oncology market and generating billions of dollars in annual revenue.
The FDA approved Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, establishing the organization's leadership in the cardiovascular market and generating over $13.0 billion in annual revenue by FY2024.
The organization completed the $74.0 billion acquisition of Celgene, securing full ownership of the hematology franchise led by Revlimid and Pomalyst, and integrating Celgene's world-class immunology and inflammation research capabilities directly into its global R&D pipeline.
The organization deployed $33.0 billion to acquire Karuna Therapeutics ($14.0B), Mirati Therapeutics ($5.8B), and RayzeBio ($4.1B), securing exclusive rights to next-generation modalities in neuroscience (Cobenfy), targeted oncology (KRAS inhibitors), and radiopharmaceuticals, fundamentally transforming the portfolio.
The organization reported consolidated net revenues of $45.0 billion for FY2024, with the Pharmaceuticals division contributing the vast majority of this total through the sale of high-margin biologics, small molecules, and targeted therapies, while allocating approximately $10.5 billion to research and development.
The FDA approved Cobenfy (xanomeline and trospium chloride), the first muscarinic agonist for the treatment of schizophrenia in over 30 years, representing a major breakthrough in neuroscience and a potential blockbuster asset for the organization.
The organization completed the full acquisition of Celgene for $74.0 billion to secure full ownership of the hematology franchise led by Revlimid and Pomalyst, and to integrate Celgene's world-class immunology and inflammation research capabilities directly into its global R&D pipeline.
The organization acquired Karuna Therapeutics for $14.0 billion to secure exclusive rights to KarXT (Cobenfy), a novel muscarinic agonist for the treatment of schizophrenia, marking a decisive and aggressive entry into the highly lucrative neuroscience therapeutic area.
The organization acquired Mirati Therapeutics for $5.8 billion to secure exclusive rights to the KRAS inhibitor franchise, targeting the notoriously difficult-to-drug G12C and G12D mutations found in a significant percentage of non-small cell lung cancer, colorectal cancer, and pancreatic cancer cases.
The organization acquired RayzeBio for $4.1 billion to establish its leadership in the rapidly growing field of radiopharmaceutical therapies, securing a proprietary actinium-225 and yttrium-90 pipeline targeting somatostatin receptor-expressing neuroendocrine tumors and prostate-specific membrane antigen-expressing prostate cancers.
Bristol-Myers Squibb formed in October 1989 through the $12.7 billion merger of Bristol-Myers Company (founded 1887 as patent medicine and personal products company) and Squibb Corporation (founded 1858, pioneering pharmaceutical manufacturer including ether anesthesia and the Pure Food and Drug Act compliance). The merger combined Bristol-Myers's consumer products and pharmaceutical franchises (Excedrin, Bufferin, prescription drugs) with Squibb's research-intensive pharmaceutical pipeline including cardiovascular drugs Capoten and Pravachol. The combined company immediately ranked among top global pharmaceutical companies with $9 billion revenue, providing scale to fund expensive drug development and global commercialisation. The integration challenges and cultural differences between Bristol-Myers's marketing-focused culture and Squibb's research-driven culture persisted for years, with strategic clarity emerging only after subsequent management changes.
BMS acquired Celgene Corporation for $74 billion in November 2019 (BMS's largest acquisition ever), gaining multiple myeloma blockbuster Revlimid ($12 billion in 2019 sales), oncology pipeline including CAR-T cell therapies (Breyanzi, Abecma), and Otezla psoriasis drug. The deal positioned BMS as oncology leader with $20+ billion in oncology revenue, though it required divesting Otezla to Amgen for $13.4 billion (regulatory requirement) and accepting $11 billion in cumulative net long-term debt. Revlimid faces patent expiry threats from generic competition starting 2022, with sales declining from $12 billion peak to projected $5-6 billion by 2026, creating revenue replacement challenge that defined post-acquisition strategy. The deal exemplifies pharmaceutical industry consolidation logic — acquiring patent-protected revenue streams to fund pipeline investment — but with significant integration and patent cliff execution risks.
BMS launched Opdivo (nivolumab) in 2014 as the first PD-1 immune checkpoint inhibitor — alongside Merck's Keytruda — for melanoma and lung cancer, pioneering the immunotherapy approach that has revolutionised cancer treatment over the following decade. Opdivo grew to $7+ billion annual peak revenue but lost early-mover advantage to Keytruda which surpassed Opdivo by 2018 due to superior lung cancer trial results and execution. The competitive lessons from Opdivo's loss of leadership position despite first-mover advantage shaped BMS's subsequent oncology strategy emphasising combination therapies, broader cancer indications, and earlier disease-stage treatments. Opdivo continues generating $9+ billion annually in 2024 and remains BMS's largest single product, but the competitive setback versus Keytruda created cultural urgency around oncology execution that influences current strategy.
BMS faces simultaneous patent expirations including Revlimid (peak $12 billion, declining to projected $5-6 billion by 2026), Eliquis cardiovascular (peak $13 billion, US patent expires 2026), and Opdivo (peak $9 billion, gradual erosion through 2030+), totaling $20+ billion in revenue at risk over the next 5-7 years. The company's revenue replacement strategy includes recently launched Reblozyl (anemia), Camzyos (hypertrophic cardiomyopathy), Sotyktu (psoriasis), and Cobenfy (schizophrenia), plus advanced pipeline including Milvexian anticoagulant and various oncology combinations. Achieving $50+ billion total revenue by 2030 requires the new launches reaching $10-15 billion combined while patent-expired products lose only $20+ billion — a challenging mathematical execution that depends on commercial success of multiple new launches occurring during the patent cliff window.
Plavix (clopidogrel), the antiplatelet drug co-marketed with Sanofi, was the second-best-selling prescription medicine in the world by the late 2000s and generated roughly $7.1 billion in BMS revenue in 2011, about 33% of BMS's total pharmaceutical sales that year. On May 17, 2012 the U.S. patent expired and generic clopidogrel from Mylan, Teva, Apotex, and others entered the market overnight, collapsing Plavix sales by about 96% within a single quarter and roughly $5 to $6 billion off BMS's annual revenue run-rate. CEO Lamberto Andreotti's response, the 'String of Pearls' strategy first articulated in 2007, accelerated: BMS had already spent roughly $11 billion between 2007 and 2012 acquiring Adnexus (2007, $430 million), Kosan Biosciences (2008, $190 million), Medarex (2009, $2.4 billion, the deal that brought in the future Opdivo molecule), ZymoGenetics (2010, $885 million), Inhibitex (2012, $2.5 billion), and Amylin Pharmaceuticals (2012, $5.3 billion). The Medarex deal in particular seeded the immuno-oncology pipeline that produced Yervoy (approved 2011) and Opdivo (approved 2014), drugs that more than replaced Plavix revenue by 2017. The cliff also drove BMS to divest its Mead Johnson nutrition business in 2009 and to exit consumer health products, completing its transition from diversified healthcare company to focused biopharma.